Advances in Lipid-Based Pulmonary Nanomedicine for The Management of Inflammatory Lung Disorders

References

• Haque S, Whittaker MR, McIntosh MP, Pouton CW, Kaminskas LM. Disposition and safety of inhaled biodegradable nanomedicines: opportunities and challenges. Nanomedicine 12(6), 1703–1724 (2016).
   PubMed Web of Science ®Google Scholar
• Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv. Drug Deliv. Rev. 157, 161–178 (2020).
   PubMed Web of Science ®Google Scholar
• Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther. Deliv. 8(8), 647–661 (2017).
   PubMed Web of Science ®Google Scholar
• Kumar M, Jha A, Dr M, Mishra B. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy. Expert Opin. Drug Deliv. 17(10), 1459–1472 (2020).
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res. Pharm. Sci. 13(4), 288–303 (2018).
   PubMed Web of Science ®Google Scholar
• Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 11(3), 1841–1851 (2011).
   PubMed Web of Science ®Google Scholar
• Dabbagh A, Abu Kasim NH, Yeong CH, Wong TW, Abdul Rahman N. Critical parameters for particle-based pulmonary delivery of chemotherapeutics. J. Aerosol Med. Pulm. Drug Deliv. 31(3), 139–154 (2017).
   PubMed Web of Science ®Google Scholar
• Deniz A, Sade A, Severcan F, Keskin D, Tezcaner A, Banerjee S. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Biosci. Rep. 30(5), 365–373 (2010).
   PubMed Web of Science ®Google Scholar
• Chiong HS, Yong YK, Ahmad Z et al. Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages. Int. J. Nanomed. 8, 1245–1255 (2013).
   PubMed Web of Science ®Google Scholar
• Khan I, Hussein S, Houacine C et al. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers. Int. J. Pharm. 598, 120376 (2021).
   PubMedGoogle Scholar
• Shadambikar G, Marathe S, Ji N et al. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int. J. Pharm. X 3, 100074 (2021).
   PubMedGoogle Scholar
• Khan I, Needham R, Yousaf S et al. Impact of phospholipids, surfactants and cholesterol selection on the performance of transfersomes vesicles using medical nebulizers for pulmonary drug delivery. J. Drug Deliv. Sci. Technol. 66, 102822 (2021).
   Web of Science ®Google Scholar
• Honmane S, Hajare A, More H, Osmani RAM, Salunkhe S. Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. J. Liposome Res. 29(4), 332–342 (2019).
   PubMed Web of Science ®Google Scholar
• Tahara K, Tomida H, Ito Y et al. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects. Int. J. Pharm. 505(1), 139–146 (2016).
   PubMedGoogle Scholar
• Zhang L-J, Xing B, Wu J, Xu B, Fang X-L. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm. Pharmacol. Ther. 21(1), 239–246 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, Woods A, Riffo-Vasquez Y et al. Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration. J. Control. Release 235, 24–33 (2016).
   PubMed Web of Science ®Google Scholar
• Carlier FM, de Fays C, Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front. Physiol. 12, 691227 (2021).
   PubMed Web of Science ®Google Scholar
• Murgia X, Carvalho C de S, Lehr C-M. Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. Eur. J. Nanomed. 6(3), 157–169 (2014).
   Google Scholar
• Alp G, Aydogan N. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer. Eur. J. Pharm. Biopharm. 149, 45–57 (2020).
   PubMed Web of Science ®Google Scholar
• Zhao J, Su J, Qin L, Zhang X, Mao S. Exploring the influence of inhaled liposome membrane fluidity on its interaction with pulmonary physiological barriers. Biomater. Sci. 8(23), 6786–6797 (2020).
   PubMed Web of Science ®Google Scholar
• Li Z, Qiao W, Wang C et al. DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment. Drug Deliv. 27(1), 736–744 (2020).
   PubMed Web of Science ®Google Scholar
• Keum H, Kim J, Yoo D et al. Biomimetic lipid nanocomplexes incorporating STAT3-inhibiting peptides effectively infiltrate the lung barrier and ameliorate pulmonary fibrosis. J. Control. Release 332, 160–170 (2021).
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe A, Kyadarkunte A, Patole M, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro–in vivo aerosol performance. Eur. J. Pharm. Biopharm. 88(1), 169–177 (2014).
   PubMed Web of Science ®Google Scholar
• Wang Q, Mi G, Hickey D et al. Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia. Biomaterials 160, 107–123 (2018).
   PubMed Web of Science ®Google Scholar
• Lorenzoni R, Cordenonsi LM, Davies S et al. Lipid-core nanocapsules are an alternative to the pulmonary delivery and to increase the stability of statins. J. Microencapsul. 36(4), 317–326 (2019).
   PubMed Web of Science ®Google Scholar
• Hamedinasab H, Rezayan AH, Mellat M, Mashreghi M, Jaafari MR. Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine. Int. J. Biol. Macromol. 156, 1455–1463 (2020).
   PubMed Web of Science ®Google Scholar
• Yu S, Wang S, Zou P et al. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. Int. J. Pharm. 575, 118915 (2020).
   PubMedGoogle Scholar
• Hureaux J, Lacoeuille F, Lagarce F et al. Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats. Int. J. Nanomed. 12, 8159–8170 (2017).
   PubMed Web of Science ®Google Scholar
• Yu Z, Liu X, Chen H, Zhu L. Naringenin-loaded dipalmitoylphosphatidylcholine phytosome dry powders for inhaled treatment of acute lung injury. J. Aerosol Med. Pulm. Drug Deliv. 33(4), 194–204 (2020).
   PubMed Web of Science ®Google Scholar
• Li M, Zhang T, Zhu L, Wang R, Jin Y. Liposomal andrographolide dry powder inhalers for treatment of bacterial pneumonia via anti-inflammatory pathway. Int. J. Pharm. 528(1–2), 163–171 (2017).
   PubMedGoogle Scholar
• Wijagkanalan W, Higuchi Y, Kawakami S, Teshima M, Sasaki H, Hashida M. Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol. Pharmacol. 74(5), 1183–1192 (2008).
   PubMed Web of Science ®Google Scholar
• Kim G, Lee Y, Ha J, Han S, Lee M. Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation. J. Control. Release 330, 684–695 (2021).
   PubMed Web of Science ®Google Scholar
• Cingolani E, Alqahtani S, Sadler RC, Prime D, Stolnik S, Bosquillon C. In vitro investigation on the impact of airway mucus on drug dissolution and absorption at the air–epithelium interface in the lungs. Eur. J. Pharm. Biopharm. 141, 210–220 (2019).
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Cruz A, Pérez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur. J. Pharm. Biopharm. 95, 117–127 (2015).
   PubMed Web of Science ®Google Scholar
• Nafee N, Makled S, Boraie N. Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization. Eur. J. Pharm. Sci. 125, 151–162 (2018).
   PubMed Web of Science ®Google Scholar
• Bujan A, Alonso S del V, Chiaramoni NS. Lipopolymers and lipids from lung surfactants in association with N-acetyl-L-cysteine: characterization and cytotoxicity. Chem. Phys. Lipids 231, 104936 (2020).
   PubMed Web of Science ®Google Scholar
• Haque S, Feeney O, Meeusen E et al. Local inflammation alters the lung disposition of a drug loaded PEGylated liposome after pulmonary dosing to rats. J. Control. Release 307, 32–43 (2019).
   PubMed Web of Science ®Google Scholar
• Yeganeh EM, Bagheri H, Mahjub R. Preparation, statistical optimization and in-vitro characterization of a dry powder inhaler (DPI) containing solid lipid nanoparticles encapsulating amphotericin B: ion paired complexes with distearoyl phosphatidylglycerol. Iran. J. Pharm. Res. 19(3), 45–62 (2020).
   Web of Science ®Google Scholar
• Wang J-L, Hanafy MS, Xu H et al. Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery. Int. J. Pharm. 596, 120215 (2021).
   PubMedGoogle Scholar
• Umerska A, Mouzouvi CRA, Bigot A, Saulnier P. Formulation and nebulization of fluticasone propionate-loaded lipid nanocarriers. Int. J. Pharm. 493(1), 224–232 (2015).
   PubMedGoogle Scholar
• Gomez AI, Acosta MF, Muralidharan P et al. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery. Pulm. Pharmacol. Ther. 64, 101975 (2020).
   PubMed Web of Science ®Google Scholar
• Szabová J, Mišík O, Havlíková M, Lízal F, Mravec F. Influence of liposomes composition on their stability during the nebulization process by vibrating mesh nebulizer. Colloids Surf. B Biointerfaces 204, 111793 (2021).
   PubMed Web of Science ®Google Scholar
• Ji P, Yu T, Liu Y et al. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des. Devel. Ther. 10, 911–925 (2016).
   PubMed Web of Science ®Google Scholar
• Ourique AF, dos Santos Chaves P, Souto GD, Pohlmann AR, Guterres SS, Beck RCR. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity. Eur. J. Pharm. Sci. 65, 174–182 (2014).
   PubMed Web of Science ®Google Scholar
• Poyner EA, Alpar HO, Almeida AJ, Gamble MD, Brown MRW. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J. Control. Release 35(1), 41–48 (1995).
   Web of Science ®Google Scholar
• Liu Y, Bos IST, Oenema TA, Meurs H, Maarsingh H, Hirsch AK. Delivery system for budesonide based on lipid-DNA. Eur. J. Pharm. Biopharm. 130, 123–127 (2018).
   PubMed Web of Science ®Google Scholar
• Komalla V, Allam VSRR, Kwok PCL et al. A phospholipid-based formulation for the treatment of airway inflammation in chronic respiratory diseases. Eur. J. Pharm. Biopharm. 157, 47–58 (2020).
   PubMed Web of Science ®Google Scholar
• Ng ZY, Wong J-Y, Panneerselvam J et al. Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma. Colloids Surf. B Biointerfaces 172, 51–59 (2018).
   PubMed Web of Science ®Google Scholar
• Nassimi M, Schleh C, Lauenstein HD et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 75(2), 107–116 (2010).
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang Y, Wang W et al. Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery. J. Control. Release 325, 206–222 (2020).
   PubMed Web of Science ®Google Scholar
• Esmaeili M, Aghajani M, Abbasalipourkabir R, Amani A. Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior. Artif. Cells Nanomed. Biotechnol. 44(8), 1964–1971 (2016).
   PubMed Web of Science ®Google Scholar
• Moreno-Sastre M, Pastor M, Esquisabel A et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int. J. Pharm. 498(1–2), 263–273 (2016).
   PubMedGoogle Scholar
• Tran T-T, Yu H, Vidaillac C et al. An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis. Int. J. Pharm. 559, 382–392 (2019).
   PubMedGoogle Scholar
• Torge A, Wagner S, Chaves PS et al. Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. Int. J. Pharm. 527(1), 92–102 (2017).
   PubMedGoogle Scholar
• de Lima PHC, Butera AP, Cabeça LF, Ribeiro-Viana RM. Liposome surface modification by phospholipid chemical reactions. Chem. Phys. Lipids 237, 105084 (2021).
   PubMed Web of Science ®Google Scholar
• Miyazawa T, Itaya M, Burdeos GC, Nakagawa K, Miyazawa T. A critical review of the use of surfactant-coated nanoparticles in nanomedicine and food nanotechnology. Int. J. Nanomedicine 16, 3937–3999 (2021).
   PubMed Web of Science ®Google Scholar
• Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A. Size, shape, charge and ‘stealthy’ surface: carrier properties affect the drug circulation time in vivo. Asian J. Pharm. Sci. 16(4), 444–458 (2021).
   PubMed Web of Science ®Google Scholar
• Chen X, Liu L, Jiang C. Charge-reversal nanoparticles: novel targeted drug delivery carriers. Acta Pharm. Sin. B 6(4), 261–267 (2016).
   PubMed Web of Science ®Google Scholar
• Haque S, Whittaker M, McIntosh MP, Pouton CW, Phipps S, Kaminskas LM. A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. Eur. J. Pharm. Biopharm. 125, 1–12 (2018).
   PubMed Web of Science ®Google Scholar
• Shetty N, Hou J, Yanez E et al. Effect of lipidic excipients on the particle properties and aerosol performance of high drug load spray dried particles for inhalation. J. Pharm. Sci. doi: 10.1016/j.xphs.2021.09.004 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Vartiainen V, Raula J, Bimbo LM et al. Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. Int. J. Pharm. 544(1), 121–128 (2018).
   PubMedGoogle Scholar
• Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® technology. Eur. J. Pharm. Biopharm. 166, 10–18 (2021).
   PubMed Web of Science ®Google Scholar
• Emami J, Mohiti H, Hamishehkar H, Varshosaz J. Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box–Behnken design. Res. Pharm. Sci. 10(1), 17–33 (2015).
   PubMed Web of Science ®Google Scholar
• Qin Y, Li Z, Yang Y et al. Liposomes formulated with fMLP-modified cholesterol for enhancing drug concentration at inflammatory sites. J. Drug Target. 22(2), 165–174 (2014).
   PubMed Web of Science ®Google Scholar
• Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur. J. Pharm. Sci. 38(2), 165–171 (2009).
   PubMed Web of Science ®Google Scholar
• Bonde S, Tambe K. Lectin coupled liposomes for pulmonary delivery of salbutamol sulphate for better management of asthma: formulation development using QbD approach. J. Drug Deliv. Sci. Tech. 54, 101336 (2019).
   Web of Science ®Google Scholar
• Murata M, Tahara K, Takeuchi H. Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration. Eur. J. Pharm. Biopharm. 86(1), 115–119 (2014).
   PubMed Web of Science ®Google Scholar
• Patil HP, Freches D, Karmani L et al. Fate of PEGylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation. J. Control. Release 272, 62–71 (2018).
   PubMed Web of Science ®Google Scholar
• Manconi M, Manca ML, Valenti D et al. Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. Int. J. Pharm. 525(1), 203–210 (2017).
   PubMed Web of Science ®Google Scholar
• Pooladanda V, Thatikonda S, Sunnapu O et al. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome. Nanomedicine 33, 102351 (2021).
   PubMed Web of Science ®Google Scholar
• Santiwarangkool S, Akita H, Khalil IA et al. A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. J. Control. Release 307, 55–63 (2019).
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe A, Pokharkar V. Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design. Int. J. Pharm. 501(1–2), 199–210 (2016).
   PubMedGoogle Scholar
• De Leo V, Ruscigno S, Trapani A et al. Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int. J. Pharm. 545(1), 378–388 (2018).
   PubMedGoogle Scholar
• El-Laithy HM, Youssef A, El-Husseney SS, El Sayed NS, Maher A. Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks. Drug Deliv. 28(1), 826–843 (2021).
   PubMed Web of Science ®Google Scholar
• Togami K, Chono S, Tada H. Alteration in intrapulmonary pharmacokinetics of aerosolized model compounds due to disruption of the alveolar epithelial barriers following bleomycin-induced pulmonary fibrosis in rats. J. Pharm. Sci. 105(3), 1327–1334 (2016).
   PubMed Web of Science ®Google Scholar
• Chennakesavulu S, Mishra A, Sudheer A, Sowmya C, Suryaprakash Reddy C, Bhargav E. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis. Asian J. Pharm. Sci. 13(1), 91–100 (2018).
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J. Control. Release 296, 225–231 (2019).
   PubMed Web of Science ®Google Scholar
• Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur. J. Pharm. Biopharm. 84(2), 335–344 (2013).
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Ghaffari S, Mirshojaei SF et al. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. Biomed. Res. Int. 2013, 136859 (2013).
   PubMed Web of Science ®Google Scholar
• Gregory TJ, Steinberg KP, Spragg R et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 155(4), 1309–1315 (1997).
   PubMed Web of Science ®Google Scholar
• Insmed Inc. Long term safety and tolerability study of open-label liposomal amikacin for inhalation (ARIKACE™) in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. https://clinicaltrials.gov/ct2/show/NCT01316276
   Google Scholar
• Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384(5), 403–416 (2021).
   PubMed Web of Science ®Google Scholar
• Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. J. Control. Release 333, 511–520 (2021).
   PubMed Web of Science ®Google Scholar
• Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv. Transl. Res. 11(4), 1309–1315 (2021).
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4(3), e10143 (2019).
   PubMed Web of Science ®Google Scholar
• Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33(10), 2373–2387 (2016).
   PubMed Web of Science ®Google Scholar
• Fenton OS, Olafson KN, Pillai PS, Mitchell MJ, Langer R. Advances in biomaterials for drug delivery. Adv. Mater. 30(29), 1705328 (2018).
   Web of Science ®Google Scholar